Seagen Inc. could be the first to bring a drug to market for HER2-positive metastatic colorectal cancer (mCRC) if the US Food and Drug Administration approves Tukysa (tucatinib) for the expanded indication based on positive Phase II data.
The company is poised to seek accelerated approval from the FDA for the drug in second-line HER2-positive mCRC based on the positive results of the MOUNTAINEER trial, detailed on 2 July at the European Society
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?